May lead to increase exposure w/ strong P-gp inhibitors (ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir & amiodarone). Exposure may be decreased w/ strong P-gp inducers (rifampicin, carbamazepine, phenytoin, phenobarb or St. John's wort). Decreased exposure w/ high-fat meal. May increase bioavailability of BCRP substrates (rosuvastatin & sulfasalazine).